NexImmune Completes Sr. Leadership Team With New VP Hires
- Naimish Pandya, MD assumes role of VP & Head, Clinical Development
- Alex Matschiner, MS ChE assumes role of VP, Protein Process Development
GAITHERSBURG, Md., Dec. 04, 2018 (GLOBE NEWSWIRE) — NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced the hiring of two new Vice Presidents. Naimish Pandya, MD has been hired as Vice President & Head of Clinical Development. In addition, Alex Matschiner, MS has been hired as Vice President of Protein Process Development.
“I am thrilled to welcome both Naimish and Alex to our team,” said Scott Carmer, Chief Executive Officer of NexImmune. “They each bring a wealth of experience and specific expertise in the biotechnology industry and will add significant value to our Sr. Leadership Team as we bring our AIM ACT products into initial early clinical development.”
Naimish Pandya, MD
Naimish Pandya, MD is a board-certified medical oncologist/internist with ~7 years in progressive oncology and immuno-oncology clinical development experience in biotechnology and pharma. Prior to joining NexImmune, he was Executive Medical Director & Head of Clinical Development at Northern Biologics, where he ran the MSC-1 program, the company’s lead immuno-oncology antibody candidate targeting the tumor microenvironment. Previously, Naimish was Senior Medical Director of Clinical Research & Development at MacroGenics, where he led two IND filings, and was responsible for overseeing three Phase 1 studies and global Phase 2 and 3 studies, as part of the company’s bispecific DART® platform and their antibody development programs, including their anti-PD-1 and anti-HER2 molecules. Prior to his industry experience, Naimish was faculty at the University of Maryland Greenebaum Cancer Center. He received his medical degree from Temple University and completed his oncology training at Thomas Jefferson University in Philadelphia.
Alex Matschiner, MS ChE
Alex Matschiner is a seasoned biotech industry professional with over 20 years of experience spanning start-ups through large companies, with previous roles in business operations, process development, scale-up, tech-transfer, and cGMP manufacturing; bioprocess engineering and cGMP facility design/build, start-up and validation; and project management. Prior to joining NexImmune, Alex was a consultant for multiple local biotech companies focused on process development and engineering and previously served as COO at BioFactura. He also held a Senior Scientist role in MS&T at MedImmune/Astrazeneca, and was a Senior Manager at Human Genome Sciences in different roles including Project Management, Manufacturing, and Process Engineering.
NexImmune is a biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics. The Company’s proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to create highly targeted T cell-based immunotherapies. In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system. For more information visit: www.neximmune.com
The Leukemia & Lymphoma Society is a NexImmune partner for the clinical development of AIM ACT.
Latest posts by Chris Frew (see all)
- The Right Strategies for Scientists to Achieve Career Success in Industry - June 11, 2019
- BIO 2019 Showcases Philadelphia as a City Where the Story of Gene Therapy has Come Full Circle - June 3, 2019
- This Maryland BioPharma is Preparing for Massive Growth by Showcasing its Mission, Culture and People - May 29, 2019